SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
CytRx Corporation Receives Recommendation from Data Safety Monitoring Committee to Complete Global Phase 2b Clinical Trial With Tamibarotene as First-Line Treatment for Non-Small-Cell Lung Cancer